PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。